This disclosure provides novel neutralizing and potent anti-SARS-CoV-2 antibodies, related nucleic acids, related cells, related kits, related compositions, and related methods or uses.
Embodiments of the present invention are directed to compositions and methods for anti-HIV (anti-CD4 binding site) potent VRC01-like (PVL) antibodies targeted to gp120 having an amino acid substitution at a residue in the anti-CD4 binding site PVL antibody that is equivalent to Phe43 in CD4, these antibodies having improved potency and breadth.
This disclosure is based, at least in part, on an unexpected discovery that novel combination therapies of an anti-CD40 antibody or antigen binding fragment thereof and an IL-15 polypeptide exhibit synergistic activity in inhibiting tumor growth than any of the monotherapies of the anti-CD40 antibody or antigen binding fragment thereof and the IL-15 polypeptide. Thus, the combination therapy as disclosed herein represents a surprisingly effective therapy for cancer treatment with a reduced risk of treatment-related toxicity.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A multiplexing module implements receiving a plurality of laser pulses from a pulsed laser source via an input coupler element; splitting each laser pulse into a plurality of beamlets; introducing a delay between adjacent beamlets of the plurality of beamlets; and outputting a plurality of beamlets associated with each respective laser pulse via an output coupler element, wherein the input coupler and the output coupler are separate elements of the multiplexing module.
The present invention provides biological markers which are molecular markers and predictive of brain pathology and clinical status and/or outcome in Parkinson's disease (PD). The invention provides genes, RNA and protein markers that are associated with, relevant to, or predictive of Parkinson's disease (PD), Parkinson's disease with dementia (PDD), Parkinson's disease with dyskinesia or Parkinson's disease duration. The present invention further provides methods, kits and markers for the identification and monitoring of disease and disease aspects in Parkinson's patients and their application as markers and targets in and for evaluating, monitoring and treatment of Parkinson's disease and relevant pathologies and conditions associated with or developing in Parkinson's disease.
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
G16B 20/00 - TIC spécialement adaptées à la génomique ou protéomique fonctionnelle, p. ex. corrélations génotype-phénotype
6.
1-OXOISOINDOLIN-2-YL AMIDE ACTIVATORS OF VCP AND DERIVATIVES THEREOF
Compositions and methods for stimulating VCP activity and treating various degenerative diseases are disclosed. 1-oxoisoindolin-2-yl amides of the following formula (I) stimulate VCP activity and are therefore useful for treating various degenerative diseases.
N-(3-substituted thiazaheterocyclylidene)-1H-pyrrolo[2,3-b]pyridine-3-carboxamides, N-(3-substituted thiazaheterocyclylidene)-1H-pyrrolo[2,3-b]pyridine-4-carboxamides and N-(3-substituted thiazaheterocyclylidene)-1H-pyrrolo[3,2-b]pyridine-1-carboxamides
N-(3-substituted thiazaheterocyclylidene)-1H-pyrrolo[2,3-b]pyridine-3-carboxamides, N-(3-substituted thiazaheterocyclylidene)-1H-pyrrolo[2,3-b]pyridine-4-carboxamides and N-(3-substituted thiazaheterocyclylidene)-1H-pyrrolo[3,2-b]pyridine-1-carboxamides
wherein the ring designated Q or Q′ is a five-, six-, or seven-membered heterocycle containing one sulfur and one nitrogen are disclosed. The compounds activate Yap and inhibit Lats kinases. They are therefore useful for treating hearing loss.
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p.ex. indolizine, bêta-carboline
A61K 31/444 - Pyridines non condensées; Leurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p.ex. amrinone
A61K 31/4985 - Pyrazines ou pipérazines condensées en ortho ou en péri avec des systèmes hétérocycliques
A61K 31/5377 - 1,4-Oxazines, p.ex. morpholine non condensées et contenant d'autres hétérocycles, p.ex. timolol
A61K 31/541 - Thiazines non condensées contenant d'autres hétérocycles
A61K 31/554 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p.ex. azélastine, pentylènetétrazole ayant au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p.ex. clothiapine, diltiazem
C07D 519/00 - Composés hétérocycliques contenant plusieurs systèmes de plusieurs hétérocycles déterminants condensés entre eux ou condensés avec un système carbocyclique commun non prévus dans les groupes ou
8.
EXPANDING AND IMPROVING NANOBODY REPERTOIRES: TARGETING SARS-COV-2
SEATTLE CHILDREN'S HOSPITAL DBA SEATTLE CHILDREN'S RESEARCH INSTITUTE (USA)
Inventeur(s)
Cross, Frederick R.
Rout, Michael P.
Chait, Brian T.
Aitchison, John D.
Fridy, Peter
Ketaren, Natalia
Mast, Fred
Olivier, Paul
Abrégé
Provided are anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) VHH antibodies, and methods of making and using the VHH chain antibodies.
The invention provides a polypeptide containing at least one IgG Fc region, wherein said at least one IgG Fc region is glycosylated with at least one galactose moiety connected to a respective terminal sialic acid moiety by a α 2,6 linkage, and wherein said polypeptide having a higher anti-inflammatory activity as compared to an unpurified antibody.
C07K 16/00 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p.ex. un fragment Fc
C07K 16/06 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux provenant de sérum
C07K 16/18 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
C12P 21/00 - Préparation de peptides ou de protéines
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
10.
COMPOSITIONS COMPRISING AN MTOR INHIBITOR FOR USE IN TREATING DISEASES AND DISORDERS ASSOCIATED WITH LEPTIN RESISTANCE AND OBESITY
The present invention provides compositions comprising mTOR inhibitors and their use for sensitizing cells to leptin and for treating or preventing diseases or disorders associated with leptin deficiency or leptin resistance.
Methods and compositions for treating SARS-CoV-2 and COVID-19 are disclosed. Sulfonamide-1H-pyrrole-2-carboxamides of the following formula inhibit the SARS-CoV-2 methyltransferase enzyme NSP14 and are therefore useful for treating SARS-CoV-2 and COVID-19.
A61K 31/166 - Amides, p.ex. acides hydroxamiques ayant des cycles aromatiques, p.ex. colchicine, aténolol, progabide ayant l'atome de carbone d'un groupe carboxamide lié directement au cycle aromatique, p.ex. procaïnamide, procarbazine, métoclopramide, labétalol
Methods and compositions for treating SARS-CoV-2 and COVID-19 are disclosed. 1,3-indole propanamides of the following formula (I) inhibit the SARS-CoV-2 PLpro/NSP3 protein and are therefore useful for treating SARS-CoV-2 and COVID-19.
Methods and compositions for treating SARS-CoV-2 and COVID-19 are disclosed. Sulfone-1H-pyrrole-2-carboxamides of the following formula inhibit the SARS-CoV-2 PLpro/NSP3 protein and are therefore useful for treating SARS-CoV-2 and COVID-19.
A61K 31/166 - Amides, p.ex. acides hydroxamiques ayant des cycles aromatiques, p.ex. colchicine, aténolol, progabide ayant l'atome de carbone d'un groupe carboxamide lié directement au cycle aromatique, p.ex. procaïnamide, procarbazine, métoclopramide, labétalol
The invention provides broadly neutralizing antibodies directed to epitopes of Human Immunodeficiency Virus, or HIV. The invention further provides compositions containing HIV antibodies used for prophylaxis, and methods for diagnosis and treatment of HIV infection.
C07K 16/10 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
G01N 33/569 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour micro-organismes, p.ex. protozoaires, bactéries, virus
The present invention discloses novel agents and methods for diagnosis and treatment of melanoma. Also disclosed are related arrays, kits, and screening methods.
A61K 31/195 - Acides carboxyliques, p.ex. acide valproïque ayant un groupe amino
A61K 31/136 - Amines, p.ex. amantadine ayant des cycles aromatiques, p.ex. méthadone ayant le groupe amino lié directement au cycle aromatique, p.ex. benzène-amine
A61K 31/5377 - 1,4-Oxazines, p.ex. morpholine non condensées et contenant d'autres hétérocycles, p.ex. timolol
A61K 31/675 - Composés du phosphore ayant l'azote comme hétéro-atome d'un cycle, p.ex. phosphate de pyridoxal
A61K 38/17 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur
C07C 217/54 - Composés contenant des groupes amino et hydroxy éthérifiés liés au même squelette carboné ayant des groupes hydroxy éthérifiés liés à des atomes de carbone d'au moins un cycle aromatique à six chaînons et des groupes amino liés à des atomes de carbone acycliques ou à des atomes de carbone de cycles autres que des cycles aromatiques à six
C07D 233/64 - Composés hétérocycliques contenant des cycles diazole-1, 3 ou diazole-1, 3 hydrogéné, non condensés avec d'autres cycles comportant deux liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des radicaux hydrocarbonés substitués, liés aux atomes de carbone du cycle, p.ex. histidine
C07F 9/6506 - Cycles à cinq chaînons les atomes d'azote étant en positions 1 et 3
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
G01N 33/574 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour le cancer
17.
NEUTRALIZING ANTI- SARS-COV-2 ANTIBODIES AND METHODS OF USE THEREOF
This disclosure provides novel neutralizing anti-SARS-COV-2 antibodies or antigen-binding fragments thereof. The disclosed anti-SARS-COV-2 antibodies constitute a novel therapeutic strategy in protection from SARS-COV-2 infections.
C07K 16/10 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p.ex. un fragment Fc
18.
METHODS OF TREATING ADENOCARCINOMA WITH HUMAN MICROBIOTA DERIVED N-ACYL AMIDES
The presently claimed and described technology provides methods of treating adenocarcinoma in a subject by administering a genetically engineered cell expressing a human microbial N-acyl synthase (hm-NAS) gene, an hm-NAS gene, an N-acyl amide, or compositions thereof.
A volumetric imaging system implements obtaining raw image data of a sample volume of a sample material, the raw image data comprising light field data of the sample volume acquired using a microlens array disposed in front of a camera; and analyzing the raw image data using an image analysis pipeline configured to localize the objects of interest in the raw image data to obtain classified image data in which the objects of interest have been identified, the image analysis pipeline being configured to process the raw image data to improve signal extraction at depth in the scattering material to maximize localization accuracy.
G06T 7/155 - Découpage; Détection de bords impliquant des opérateurs morphologiques
G06T 7/194 - Découpage; Détection de bords impliquant une segmentation premier plan-arrière-plan
G06T 7/262 - Analyse du mouvement utilisant des procédés de transformation de domaine, p.ex. des procédés de transformée de Fourier
G06T 7/70 - Détermination de la position ou de l'orientation des objets ou des caméras
G06V 10/26 - Segmentation de formes dans le champ d’image; Découpage ou fusion d’éléments d’image visant à établir la région de motif, p.ex. techniques de regroupement; Détection d’occlusion
G06V 10/82 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant les réseaux neuronaux
H04N 23/55 - Pièces optiques spécialement adaptées aux capteurs d'images électroniques; Leur montage
H04N 23/81 - Chaînes de traitement de la caméra; Leurs composants pour supprimer ou minimiser les perturbations lors de la génération de signaux d'image
Provided are compositions and methods for selectively reducing the amount of antibiotic resistant and/or virulent bacteria in a mixed bacteria population, or for reducing any other type of unwanted bacteria in a mixed bacteria population. The compositions and methods involve targeting bacteria that are differentiated from other members of the population by at least one unique clustered regularly interspaced short palindromic repeats (CRISPR) targeted DNA sequence. The compositions and methods can be readily adapted to target any bacteria or any bacteria plasmid, or both.
A01N 63/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des micro-organismes, des virus, des champignons microscopiques, des animaux ou des substances produites par, ou obtenues à partir d
A61K 31/7105 - Acides ribonucléiques naturels, c. à d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur
C12N 9/16 - Hydrolases (3.) agissant sur les liaisons esters (3.1)
A multi-photon imaging system includes a laser module having a first channel for outputting a two-photon excitation laser pulse and a second channel for outputting a three-photon excitation laser pulse. The system further includes a first optical path for guiding the two-photon laser pulse from the first channel of the laser module and a second optical path for guiding the three-photon laser pulse from the second channel of the laser module. A microscope is also provided for simultaneously receiving the two-photon laser pulse from the first optical path and the three-photon laser pulse from the second optical path, and simultaneously, or with well controllable delays, delivering the two-photon laser pulse and the three-photon pulse to a target volume. The system further includes a photodetector configured to collect photons generated within the target volume in response to simultaneous excitation of the target volume by both the two-photon laser pulse and the three-photon laser pulse.
Described herein are methods and compositions for accurate detection of cancer using ultrasensitive immunoassays, e.g., digital ELISA, to detect open reading frame 1 protein (ORF1p), which is encoded by the LINE-1 retrotransposon, in biofluids.
C07K 16/18 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
G01N 33/53 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet
G01N 33/574 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour le cancer
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
23.
DNA-COMPATIBLE WITTIG OLEFINATION OF ON-DNA PEPTIDYL-YLIDES FOR DEVELOPMENT OF ON-DNA PEPTIDOMIMETICS THROUGH DIVERSITY-ORIENTED SYNTHESIS (DOS)
The present invention provides methods of generating diverse chemical structures on DNA through Wittig olefination of novel on-DNA phosphorane ylides and Homer- Wadsworth-Emmons reaction of on-DNA β-keto phosphonates. The methods of this invention provide access to DNA-encode libraries (DELs) of diverse peptides, peptidomimetics, chalcone-based molecules, and the like.
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p.ex. un fragment Fc
A61K 47/50 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament
A61K 47/51 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification
24.
Neutralizing Anti-SARS-CoV-2 Antibodies and Methods of Use Thereof
This disclosure provides novel broadly neutralizing anti-SARS-CoV-2 antibodies or antigen-binding fragments thereof. The disclosed anti-SARS-CoV-2 antibodies constitute a novel therapeutic strategy in protection from SARS-CoV-2 infections.
C07K 16/10 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur
G01N 33/569 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour micro-organismes, p.ex. protozoaires, bactéries, virus
This disclosure is based, at least in part, on an unexpected discovery that the novel nanobodies and variants thereof are able to specifically bind afucosylated or sialylated IgG Fc glycoforms. Glycosylation of the IgG Fc domain is a major determinant of the strength and specificity of antibody effector functions, modulating the binding interactions of the Fc with the diverse family of Fcγ receptors. These Fc glycan modifications, such as removal of the core fucose residue, are newfound clinical markers for predicting severity of diseases, such as diseases caused by dengue virus (DENV) or SARS-CoV-2. However, it remains challenging to accurately distinguish specific IgG glycoforms without costly and time-intensive methods. The novel glycol-specific nanobodies and variants thereof, as disclosed herein, can be used as rapid clinical diagnostics or prognostics to risk stratify patients with viral and inflammatory diseases.
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p.ex. un fragment Fc
A61P 31/14 - Antiviraux pour le traitement des virus ARN
C12N 9/24 - Hydrolases (3.) agissant sur les composés glycosyliques (3.2)
G01N 33/569 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour micro-organismes, p.ex. protozoaires, bactéries, virus
26.
A CRISPR COUNTER-SELECTION INTERRUPTION CIRCUIT (CCIC) AND METHODS OF USE THEREOF
The present invention generally relates to compositions comprising a CRISPR based regulatory element comprising a barcode sequence that serves as a binding site for a Cas9/gRNA molecule and which alters expression of a downstream gene when bound by the Cas9/gRNA molecule.
C12N 15/74 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes procaryotes autres que E. coli, p.ex. Lactobacillus, Micromonospora
C40B 30/04 - Procédés de criblage des bibliothèques en mesurant l'aptitude spécifique à se lier à une molécule cible, p.ex. liaison anticorps-antigène, liaison récepteur-ligand
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p.ex. cellules transformées par des virus
27.
COMPOSITIONS AND METHODS FOR SYNTHESIZING MULTI-INDEXED SEQUENCING LIBRARIES
Provided herein are methods for preparing a sequencing library from a plurality of single cells that includes nucleic acids having three index sequences, as well as methods for generating an RNA sequencing library from single cells that can be used to dissect the critical regulators of gene-specific transcription, splicing, and degradation in a massive-parallel manner. Also provided herein are compositions, such as oligonucleotide sets for generating the sequencing libraries and kits for preparing the sequencing libraries.
AFFINITY CAPTURING AND DIRECTLY DETERMINING STRUCTURES OF PROTEINS AND OTHER MATERIALS ON SUPERPARAMAGNETIC BEADS BY CRYO-ELECTRON MICROSCOPY SINGLE-PARTICLE ANALYSIS
Paramagnetic beads capture a biological target molecule for cryo-electron microscope imaging. Two spacer modules extend from a periphery of the paramagnetic beads comprising a first spacer module and a second spacer module. The first spacer module binds the beads and the second spacer module binds the first spacer module. A capture module is linked to an outer location of the second spacer module. The capture module includes capture proteins that are adapted to capture target molecules. A method is also provided of using cryo-electron microcopy and the magnetic particles to image a biological target molecule.
B82Y 5/00 - Nanobiotechnologie ou nanomédecine, p.ex. génie protéique ou administration de médicaments
G01N 1/28 - Préparation d'échantillons pour l'analyse
G01N 1/42 - Traitement à basse température des échantillons, p.ex. cryofixation
G01N 23/2251 - Recherche ou analyse des matériaux par l'utilisation de rayonnement [ondes ou particules], p.ex. rayons X ou neutrons, non couvertes par les groupes , ou en mesurant l'émission secondaire de matériaux en utilisant des microsondes électroniques ou ioniques en utilisant des faisceaux d’électrons incidents, p.ex. la microscopie électronique à balayage [SEM]
The present disclosure provides biological markers which are molecular and cellular antecedents of rheumatoid arthritis (RA) flares. The present disclosure provides RNA and protein markers that can predict an RA flare one or two weeks prior to the flare. The present disclosure further provides blood circulating cells, particularly pre-inflammatory mesenchymal cells, which are cellular precursors and indicators of an impending RA flare. The present disclosure further provides methods, kits and markers for identification and monitoring of flares in RA patients and their application as markers and targets in and for treatment of rheumatoid arthritis and conditions induced or related to rheumatoid arthritis.
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
This disclosure provides novel neutralizing and potent anti-SARS-CoV-2 antibodies, related nucleic acids, related cells, related kits, related compositions, and related methods or uses.
C07K 16/10 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
A61K 39/215 - Coronaviridae, p.ex. virus de la bronchite infectieuse aviaire
A61P 31/14 - Antiviraux pour le traitement des virus ARN
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C07K 16/08 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus
Provided herein are HIV immunogens and uses thereof for generating an immune response in a subject. This disclosure further provides a method for treating or preventing a human immunodeficiency type I (HIV-I) infection in a subject using the disclosed HIV immunogens and/or antibodies generated by any of the methods disclosed herein.
Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40. Such antibodies optionally comprise Fc regions with enhanced specificity for FcγRIIb. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
33.
BROADLY NEUTRALIZING ANTIBODIES TO TICK-BORNE ENCEPHALITIS AND RELATED VIRUSES
This disclosure provides novel broadly neutralizing anti-tick-borne encephalitis virus (TBEV) antibodies. The disclosed anti-TBEV antibodies represent a novel therapeutic strategy for preventing or treating diseases or infections caused by various tick-borne flaviviruses, including TBEV.
C07K 16/10 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
A61P 31/14 - Antiviraux pour le traitement des virus ARN
G01N 33/569 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour micro-organismes, p.ex. protozoaires, bactéries, virus
34.
COMPOSITIONS AND METHODS FOR RAPID PRODUCTION OF VERSATILE SINGLE DOMAIN ANTIBODY REPERTOIRES
Provided are compositions and methods for producing large repertoires of recombinant single domain antibodies with high affinities and specificities against any antigen. Included are methods for making and identifying single domain antibodies produced by camelids, the single domain antibodies themselves, modifications of the nanobodies, expression vectors encoding the nanobodies, cDNAs encoding the nanobodies, cells comprising the expression vectors and/or cDNA, and methods of making the single domain antibodies re-combinantly Antigen-specific single domain antibodies and antigen binding fragments thereof having a Kd for the antigen in a sub-micromolar range are provided. The use of Protein M in isolating Ag-specific HCAbs, and digesting the isolated HCAbs using IdeS protease, is an aspect of this disclosure.
C07K 16/00 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
Provided herein are HIV immunogens and uses thereof for generating an immune response in a subject. This disclosure further provides a method for treating or preventing a human immunodeficiency type I (HIV-I) infection in a subject using the disclosed HIV immunogens and/or antibodies generated by any of the methods disclosed herein.
The present invention provides methods, compositions, and articles of manufacture useful for the prophylactic and therapeutic amelioration and treatment of gram-positive bacteria, and related conditions. The present invention provides compositions and methods incorporating and utilizing cationic nonribosomal lipopeptide antibiotics represented by Formulae (I)-(VI) or derivatives or variants thereof.
The current disclosure is directed to antibodies which inhibit coronaviruses, methods of making such antibodies, and the uses of such antibodies for the treatment and prevention of infection caused by coronaviruses.
A61P 31/14 - Antiviraux pour le traitement des virus ARN
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
C12N 5/073 - Cellules ou tissus embryonnaires; Cellules fœtales ou tissus fœtaux
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p.ex. cellules transformées par des virus
The present invention provides methods, compositions, and articles of manufacture useful for treatment of multidrug-resistant pathogens and related conditions. The present invention provides compositions and methods incorporating and utilizing cilagicin compounds or derivatives or variants thereof.
The invention provides broadly neutralizing antibodies directed to epitopes of Human Immunodeficiency Virus, or HIV. The invention further provides compositions containing HIV antibodies used for prophylaxis, and methods for diagnosis and treatment of HIV infection.
G01N 33/569 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour micro-organismes, p.ex. protozoaires, bactéries, virus
C07K 16/10 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
C07K 14/005 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de virus
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C07K 16/00 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux
C07K 16/08 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus
C07K 16/10 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
C07K 16/12 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de bactéries
C07K 16/30 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
41.
METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS
The invention features methods of treating disorders related to increased levels of myeloid derived suppressor cells such as cancer or infections. The disclosure also provides methods of treating cancer including combinations of LXRβ agonists and immunotherapies such as PD1 inhibitors, PDL1 inhibitors, and adoptive T-cell transfer therapy.
Seattle Children's Hospital d/b/a Seattle Children's Research Institute (USA)
Inventeur(s)
Chait, Brian T.
Rout, Michael P.
Aitchison, John
Mast, Fred David
Olivier, Jean Paul
Fenyo, David
Abrégé
Single-domain antibodies that bind the severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) spike protein are disclosed. The single-domain antibodies include binding domains that bind epitopes of the Spike ectodomain inside and outside the receptor binding domain. The single-domain antibodies can be used for multiple purposes including in the research, diagnosis, and prophylactic or therapeutic treatment of COVID-19.
C07K 16/10 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p.ex. un fragment Fc
A61K 51/10 - Anticorps ou immunoglobulines; Leurs fragments
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61P 31/14 - Antiviraux pour le traitement des virus ARN
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 16/18 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
43.
METAGENOME-GUIDED BIOSYNTHESIS AND COMPOUNDS AND METHODS OF USE THEREOF
The present invention provides methods, compositions, and articles of manufacture useful for the prophylactic and therapeutic amelioration and treatment of gram-positive bacteria, and related conditions. The present invention provides compositions and methods incorporating and utilizing antibiotics represented by Formulae (I)-(IX) or derivatives or variants thereof.
A61K 31/166 - Amides, p.ex. acides hydroxamiques ayant des cycles aromatiques, p.ex. colchicine, aténolol, progabide ayant l'atome de carbone d'un groupe carboxamide lié directement au cycle aromatique, p.ex. procaïnamide, procarbazine, métoclopramide, labétalol
A61K 31/167 - Amides, p.ex. acides hydroxamiques ayant des cycles aromatiques, p.ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p.ex. lidocaïne, paracétamol
A61K 31/055 - Phénols le noyau aromatique étant substitué par un halogène
Disclosed herein are compositions and methods for detecting oligonucleotide molecules that can be ligated with high efficiency, and methods of using the oligonucleotides to tag DNA encoded libraries and to modify existing DNA encoded libraries to incorporate new functionalities. Also disclosed are compositions for increasing DNA solubility in non-aqueous solvents and assay systems for detecting compounds or conditions that increase the solubility or durability of DEL.
C12Q 1/6811 - Méthodes de sélection pour la production ou l’élaboration d’oligonucléotides spécifiques cibles ou de molécules de liaison
C12Q 1/6837 - Couplage enzymatique ou biochimique d’acides nucléiques à une phase solide utilisant des réseaux de sondes ou des puces à sondes
C40B 30/04 - Procédés de criblage des bibliothèques en mesurant l'aptitude spécifique à se lier à une molécule cible, p.ex. liaison anticorps-antigène, liaison récepteur-ligand
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
This disclosure provides novel neutralizing and potent anti-SARS-CoV-2 antibodies, related nucleic acids, related cells, related kits, related compositions, and related methods or uses. Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) produced a worldwide pandemic, infecting over 456 million people and responsible for over 6 million deaths. In the United States, the FDA authorized the use of three vaccines encoding prefusion-stabilized SARS15 CoV-2 spike: BNT162b2 from Pfizer-BioNtech, mRNA 1273 from Moderna, and an adenovirus based vaccine, Ad26.COV2.S from Janssen (1). While both mRNA-based vaccines were initially approved as two-dose primary vaccine regimens, the replication-incompetent adenovirus (Ad) 26 vector-based Ad26.COV2.S vaccine received FDA emergency authorization as a single-shot vaccine.
C07K 14/165 - Coronaviridae, p.ex. virus de la bronchite infectieuse aviaire
A61P 31/14 - Antiviraux pour le traitement des virus ARN
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 16/00 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux
C07K 16/06 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux provenant de sérum
C07K 16/08 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus
47.
SEQUENCE SPECIFIC DEGRADATION OF SINGLE-STRANDED POLYNUCLEOTIDES WITH CARD1 NUCLEASE
Provided is an isolated or recombinantly expressed protein comprising the sequence of SEQ ID NO: 1 (CARD1), or an amino acid sequence that is at least 90% identical to the sequence of CARD1. Methods for producing and isolating the CARD1 protein are provided. Also provided are methods that include using CARD1, Cas1O and RNA obtained from a biological sample, and a guide RNA targeted to an RNA polynucleotide that may be in the biological sample, and determining whether or not the CARD1 cleaves a reporter ssDNA or reporter ssRNA that is added to the sample, to determine the presence or absence of the RNA polynucleotide. Kits for use in the assay are also provided.
NSERM(Institut National de la Santé la Recherche Médicale) (France)
Assistance Publique-Hôptiaux de Paris (APHP) (France)
Université Paris Cité (France)
Fondation Imagine (France)
Inventeur(s)
Casanova, Jean-Laurent
Abrégé
The present invention provides methods, assays and kits for assessment of patients positive for SARS-CoV-2 infection and methods of diagnosis and treatment of COVID-19 disease and for assessment and evaluation of individuals prior to vaccination with live attenuated virus vaccines, particularly including yellow fever vaccines and COVID-19 vaccines, to assess risk for vaccine-associated disease and adverse events, and for evaluation, treatment and management of patients who develop vaccine-associated disease. The invention provides methods and assays for identification and characterization of inborn errors of type I interferon immunity and also auto-antibodies against Type I IFNs that are associated with severe COVID-19 disease or that are correlated and linked with vaccine-associated disease. The invention further provides methods of diagnosing and determining altered response to or susceptibility to SARS-CoV-2 infection or to live attenuated virus vaccines and for applicable and suitable treatment of COVID-19 disease or vaccine-associated disease.
G01N 33/564 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour complexes immunologiques préexistants ou maladies auto-immunes
This disclosure is based, at least in part, on an unexpected discovery that the novel nanobodies and variants thereof are able to specifically bind afucosylated or sialylated IgG Fc glycoforms. Glycosylation of the IgG Fc domain is a major determinant of the strength and specificity of antibody effector functions, modulating the binding interactions of the Fc with the diverse family of Fey receptors. These Fc glycan modifications, such as removal of the core fucose residue, are newfound clinical markers for predicting severity of diseases, such as diseases caused by dengue virus (DENV) or SARS-CoV-2. However, it remains challenging to accurately distinguish specific IgG glycoforms without costly and time-intensive methods. The novel glycol-specific nanobodies and variants thereof, as disclosed herein, can be used as rapid clinical diagnostics or prognostics to risk stratify patients with viral and inflammatory diseases, as well as therapeutics for patient treatment.
The present invention relates to anti-HIV antibodies. Also disclosed are related methods and compositions. HIV causes acquired immunodeficiency syndrome (AIDS), a condition in humans characterized by clinical features including wasting syndromes, central nervous system degeneration and profound immunosuppression that results in life-threatening opportunistic infections and malignancies. Since its discovery in 1981, HIV type 1 (HIV-1) has led to the death of at least 25 million people worldwide.
The present invention provides methods for rapid and efficient isolation and characterization of nucleic acid, particularly RNA, from small volume and self-collected samples, particularly saliva samples, to determine the presence or absence of infectious agent RNA, particularly viral RNA, particularly infectious viral RNA, particularly coronavirus. The invention provides methods for isolation and evaluation of infectious agent RNA from saliva samples, particularly viral agents, particularly coronavirus. The invention further provides methods and strategies for pooling samples and RNA to determine the presence or absence of infectious agent RNA, particularly viral RNA, particularly infectious viral RNA, particularly coronavirus, with regard to large numbers of samples at one time and in a single pooled test format.
C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p.ex. verrerie de laboratoire; Compte-gouttes
52.
ANTIBACTERIAL SYNTHETIC-BIOINFORMATIC NATURAL PRODUCTS AND USES THEREOF
The present invention relates to novel compounds and compositions thereof that are useful as antimicrobial agents. The present invention also relates to methods of generating said antimicrobial compounds and compositions thereof as well as methods for treating or preventing a bacterial infection using said compounds or compositions thereof. The present invention further discloses methods for preventing or reducing the growth or proliferation of microorganisms.
This disclosure provides anti-SARS-CoV-2 antibodies or antigen-binding fragments thereof targeting the N-terminal domain (NTD) of the spike (S) protein. The disclosed anti-SARS-CoV-2 antibodies or antigen-binding fragments thereof have broadly neutralizing activities against several SARS-CoV-2 variants of concern. The disclosed anti- SARS-CoV-2 antibodies represent a therapeutic strategy in protecting from SARS-CoV-2 infections.
The present invention provides methods for isolation and characterization of nucleic acid, particularly RNA, from small volume and self-collected samples, including fingerstick blood samples, swabs and saliva samples. The RNA derived is intact and of sufficient quality and quantity for RNA analysis, longitudinal RNA sequencing and global transcriptomic profiling.
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
55.
MARKERS AND CELLULAR ANTECEENTS OF RHEUMATOID ARTHRITIS FLARES
The present invention provides biological markers which are molecular and cellular antecedents of rheumatoid arthritis (RA) flares. The invention provides RNA and protein markers that can predict an RA flare one or two weeks prior to the flare. The invention further provides blood circulating cells, particularly pre-inflammatory mesenchymal cells, which are cellular precursors and indicators of an impending RA flare. The present invention further provides methods, kits and markers for identification and monitoring of flares in RA patients and their application as markers and targets in and for treatment of rheumatoid arthritis and conditions induced or related to rheumatoid arthritis.
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
56.
USE OF LYTIC POLYSACCHARIDE MONOOXYGENASES, ENZYMATIC COMPOSITION CONTAINING SAME, AND DEGRADATION METHOD FOR PLASTIC POLYMERS
The present disclosure relates to the novel activity of the enzymatic composition containing lytic polysaccharide monooxygenases (LPMOs) that are bacterial (Auxiliary Activity 10, AA10) and/or fungal (Auxiliary Activity 9, AA9) for degrading polyethylene terephthalate (PET) and related plastic polymers. The genes that encode KpLPMO10A (AA10) and AfLPMO9A (AA9) were isolated from Kitasatospora papulosa and Aspergillus fischeri microorganisms, respectively. Methods such as atomic force microscopy (AFM) and X-ray photoelectron spectroscopy (XPS) detected alterations in the superficial chemical composition and morphology of the PET found in liquid bottles when treated with LPMOs. The gentle temperature conditions used during the LPMO-PET reaction suit the use of these enzymes to help canonical enzymes (PETases) deconstruct plastics, which is beneficial for the circular economy for PET.
Provided is an anti-CRISPR protein (AcrVIA1), which acts as an inhibitor of the nuclease of Cas13. Cas13 recognizes complementary viral transcripts to trigger the degradation of both host and viral RNA during the type VI CRISPR-Cas antiviral response. AcrVIA1 is provided as an isolated or recombinantly expressed protein comprising the sequence of SEQ ID NO:1, or derivatives thereof, expression vectors that encode the same sequence, and methods of making and using proteins that comprise the same sequence, or derivatives thereof, for inhibiting the function of Cas13 and/or protein complexes and/or ribonucleoprotein complexes that comprise Cas13. The disclosure further includes use of the described inhibitor protein in improved diagnostic assays that include Cas13. Inclusion of the inhibitor is expected to preclude a requirement to reverse transcribe and/or create cDNA amplifications of the particular RNA that is the subject of the analysis.
C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
58.
Highly active agonistic CD4 binding site anti-HIV antibodies (HAADS) comprising modified CDRH2 regions that improve contact with GP120
Embodiments of the present invention are directed to compositions and methods for anti-HIV (anti-CD4 binding site) potent VRC01-like (PVL) antibodies targeted to gp120 having an amino acid substitution at a residue in the anti-CD4 binding site PVL antibody that is equivalent to Phe43 in CD4, these antibodies having improved potency and breadth.
This disclosure provides modified B cells which produce heterologous antibodies and co-express cargo proteins. The modified B cells may be stimulated by binding of a cognate antigen to the heterologous antibodies. The B cells may be reduced or eliminated by contacting the heterologous antibody with an anti-idiotypic antibody. Methods of making, and using the modified B cells for prophylaxis and therapy for a variety of conditions are provided. The B cells are modified at an IgH locus, an IgK locus, and combinations thereof. Modified B cells maintain allelic exclusion.
Disclosed are compositions and methods for measuring olfactory sensitivity, olfactory resolution, and combinations thereof. Such measurements can be made during a single test, or over consecutive tests, which may be performed during a single testing period, such as in a single day, or over a series of testing periods. The tests may be performed by a health care professional, or may be conveniently self-administered by the user.
The present disclosure provides biological markers which are molecular and cellular antecedents of rheumatoid arthritis (RA) flares. The present disclosure provides RNA and protein markers that can predict an RA flare one or two weeks prior to the flare. The present disclosure further provides blood circulating cells, particularly pre-inflammatory mesenchymal cells, which are cellular precursors and indicators of an impending RA flare. The present disclosure further provides methods, kits and markers for identification and monitoring of flares in RA patients and their application as markers and targets in and for treatment of rheumatoid arthritis and conditions induced or related to rheumatoid arthritis.
G01N 33/564 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour complexes immunologiques préexistants ou maladies auto-immunes
C12Q 1/6809 - Méthodes de détermination ou d’identification des acides nucléiques faisant intervenir la détection différentielle
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p.ex. agents antirhumatismaux; Médicaments anti-inflammatoires non stéroïdiens [AINS]
62.
MARKERS AND CELLULAR ANTECEDENTS OF RHEUMATOID ARTHRITIS FLARES
The present disclosure provides biological markers which are molecular and cellular antecedents of rheumatoid arthritis (RA) flares. The present disclosure provides RNA and protein markers that can predict an RA flare one or two weeks prior to the flare. The present disclosure further provides blood circulating cells, particularly pre-inflammatory mesenchymal cells, which are cellular precursors and indicators of an impending RA flare. The present disclosure further provides methods, kits and markers for identification and monitoring of flares in RA patients and their application as markers and targets in and for treatment of rheumatoid arthritis and conditions induced or related to rheumatoid arthritis.
C12Q 1/6809 - Méthodes de détermination ou d’identification des acides nucléiques faisant intervenir la détection différentielle
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p.ex. arthrites, arthroses
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p.ex. agents antirhumatismaux; Médicaments anti-inflammatoires non stéroïdiens [AINS]
G01N 33/564 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour complexes immunologiques préexistants ou maladies auto-immunes
63.
COMPOSITIONS AND METHODS FOR GENERATING IMMUNOGLOBULIN KNOCK-IN MICE
Provided are compositions and methods that concurrently generate DNA insertions at two different genomic loci. The compositions and methods include a modified Adeno Associated Virus that contains two sequences configured for insertion into two separate mammalian chromosome loci. The method includes electroporation ribonucleoproteins that contain a Cas enzyme and guide RNAs that coordinate the insertion. The method provide for producing concurrent knock-in insertions that replace endogenous coding sequences, and can be used for producing antibodies.
An optical system for the detection of skin disease, such as melanoma, acquires images of a lesion on a subject's skin at different wavelengths and utilizes a sweeping arm rotating about the lesion in a clock-like sweep to produce diagnostically relevant metrics and classifiers from the image data so as to enhance detection of the skin disease.
A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
A61B 5/145 - Mesure des caractéristiques du sang in vivo, p.ex. de la concentration des gaz dans le sang, de la valeur du pH du sang
A61B 5/1455 - Mesure des caractéristiques du sang in vivo, p.ex. de la concentration des gaz dans le sang, de la valeur du pH du sang en utilisant des capteurs optiques, p.ex. des oxymètres à photométrie spectrale
A multiplexing module provided herein is configured to perform operations of receiving a plurality of laser pulses from a pulsed laser source; splitting each laser pulse into a plurality of beamlets; introducing a delay between each adjacent beamlet of the plurality of beamlets, such that the plurality of beamlets associated with a respective laser pulse of the plurality of laser pulses is distributed equally across a pulse repetition period associated with the pulsed laser source; changing a divergence of each subsequent beamlet of the plurality of beamlets associated with each respective laser pulse to introduce a distinguishing feature between each beamlet of the plurality of beamlet to cause each beamlet to focus on a different axial plane or lateral position of the sample; and outputting the plurality of beamlets associated with each respective laser pulse.
G02B 27/28 - Systèmes ou appareils optiques non prévus dans aucun des groupes , pour polariser
G02F 1/01 - Dispositifs ou dispositions pour la commande de l'intensité, de la couleur, de la phase, de la polarisation ou de la direction de la lumière arrivant d'une source lumineuse indépendante, p.ex. commutation, ouverture de porte ou modulation; Optique non linéaire pour la commande de l'intensité, de la phase, de la polarisation ou de la couleur
The present disclosure provides antibody-drug conjugates comprising (i) antibodies that specifically bind to Mer Tyrosine Kinase (MERTK) (e.g., human MERTK, or both human and mouse MERTK), and (ii) cytotoxic agents conjugated directly to the antibodies or conjugated to the antibodies via linkers, and compositions comprising such antibody-drug conjugates, wherein the antibodies contained in the antibody-drug conjugates agonize MERTK signaling of endothelial cells. The present disclosure also provides methods for treating cancer, by administering an antibody-drug conjugate that comprises (i) an antibody that specifically binds to MERTK and agonizes MERTK signaling of endothelial cells, and (ii) a cytotoxic agent conjugated directly to the antibody or conjugated to the antibody via a linker.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p.ex. un fragment Fc
N-(3-Substituted thiazol-2(3H)-ylidene)-1H-pyrrolo[2,3-b]pyridine-3-carboxamides and N-(3-substituted oxazol-2(3H)-ylidene)-1H-pyrrolo[2,3-b]pyridine-3-carboxamides
N-(3-Substituted thiazol-2(3H)-ylidene)-1H-pyrrolo[2,3-b]pyridine-3-carboxamides and N-(3-substituted oxazol-2(3H)-ylidene)-1H-pyrrolo[2,3-b]pyridine-3-carboxamides
N-(3-Substituted thiazol-2(3H)-ylidene)-1H-pyrrolo[2,3-b]pyridine-3-carboxamides and N-(3-substituted oxazol-2(3H)-ylidene)-1H-pyrrolo[2,3-b]pyridine-3-carboxamides
are disclosed. The compounds activate Yap and inhibit Lats kinases. They are therefore useful for treating hearing loss.
The present invention provides methods, compositions, and articles of manufacture useful for treatment of multi drug-resistant pathogens and related conditions. The present invention provides compositions and methods incorporating and utilizing menaquinone-binding compounds or derivatives or variants thereof.
The invention provides a polypeptide containing at least one IgG Fc region region, said polypeptide having a higher anti-inflammatory activity and a lower cytotoxic activity as compared to an unpurified antibody and methods of production of such polypeptide.
C07K 16/00 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux
C07K 16/06 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux provenant de sérum
C07K 16/18 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
C12P 21/00 - Préparation de peptides ou de protéines
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p.ex. un fragment Fc
70.
COMBINATION OF ANTI-CD40 ANTIBODY AND IL-15 FOR TREATING CANCER
This disclosure is based, at least in part, on an unexpected discovery that novel combination therapies of an anti-CD40 antibody or antigen binding fragment thereof and an IL-15 polypeptide exhibit synergistic activity in inhibiting tumor growth than any of the monotherapies of the anti-CD40 antibody or antigen binding fragment thereof and the IL-15 polypeptide. Thus, the combination therapy as disclosed herein represents a surprisingly effective therapy for cancer treatment with a reduced risk of treatment-related toxicity.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
The present invention provides phase separation sensors capable of targeting or associating with one or more biomolecular condensate or membraneless compartment in cells. The phase separation sensors comprise at least two domains wherein a first domain comprises one or more accessory protein or molecule and a second domain comprises an artificial client protein or intrinsically disordered sequence. The artificial client protein possesses intrinsic disorder and is capable of engaging in ultra-weak phase separation-specific interactions with one or more component protein or molecule in a biomolecular condensate. Methods and applications utilizing the sensors are provided including targeting, detecting, visualizing, manipulating, monitoring a biomolecular condensate and delivering one or more functional protein, label, drug or agent to a biomolecular condensate.
A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
G01N 33/58 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des substances marquées
The presently claimed and described technology provides methods of treating an inflammatory disease or disorder of the gastrointestinal tract in a subject by administering a genetically engineered cell expressing a lectin, a modified lectin gene encoding a lectin, a lectin, or compositions thereof, wherein the lectin is a non-enzymatic protein comprising a carbohydrate-binding domain.
C07K 16/30 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
G01N 33/563 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet faisant intervenir des fragments d'anticorps
C07K 16/00 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
Methods and compositions for treating leukemia are disclosed. Acylated 6-aminoindoles, acylated 6-aminopyrrolopyridines and acylated 3-aminopyrrolo[3,2-c]pyridazines of the following formula
Methods and compositions for treating leukemia are disclosed. Acylated 6-aminoindoles, acylated 6-aminopyrrolopyridines and acylated 3-aminopyrrolo[3,2-c]pyridazines of the following formula
Methods and compositions for treating leukemia are disclosed. Acylated 6-aminoindoles, acylated 6-aminopyrrolopyridines and acylated 3-aminopyrrolo[3,2-c]pyridazines of the following formula
inhibit ENL/AF9 YEATS and are therefore useful for treating leukemia.
C07D 519/00 - Composés hétérocycliques contenant plusieurs systèmes de plusieurs hétérocycles déterminants condensés entre eux ou condensés avec un système carbocyclique commun non prévus dans les groupes ou
The present disclosure relates to a neural ectodermal lineage cellular structure, and compositions and methods related thereto. In some embodiments, the disclosure provides a geometrically isolated neural ectodermal lineage cellular structure (neuruloid) including spatially segregated neuroepithelial cells, sensory placodes, neural crest cells, and epidermal cells having radial organization around a lumen within the neuroepithelial cells. The disclosure also provides methods directed to forming the neural ectodermal lineage cellular structure. The disclosure also provides methods and platforms directed to the neural ectodermal lineage cellular structure.
C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des micro-organismes viables
76.
NEUTRALIZING ANTI-SARS- COV-2 ANTIBODIES AND METHODS OF USE THEREOF
This disclosure provides novel neutralizing anti-SARS-CoV-2 antibodies or antigen-binding fragments thereof. The disclosed anti-SARS-CoV-2 antibodies constitute a novel therapeutic strategy in protection from SARS-CoV-2 infections.
C07K 16/10 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
A61P 31/14 - Antiviraux pour le traitement des virus ARN
C12N 15/50 - Coronaviridae, p.ex. virus de la bronchite infectieuse, virus de la gastro-entérite transmissible
G01N 33/569 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour micro-organismes, p.ex. protozoaires, bactéries, virus
G01N 33/577 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet faisant intervenir des anticorps monoclonaux
A multiplexing module (200) implements receiving a plurality of laser pulses from a pulsed laser source via an input coupler element (KM1); splitting each laser pulse into a plurality of beamlets; introducing a delay between adjacent beamlets of the plurality of beamlets; and outputting a plurality of beamlets associated with each respective laser pulse via an output coupler element (M3), wherein the input coupler (KM1) and the output coupler (M3) are separate elements of the multiplexing module (200).
The present invention provides methods, compositions, and articles of manufacture useful for the prophylactic and therapeutic amelioration and treatment of gram-positive bacterial infections, including drug resistant bacterial infections, and related conditions, or inhibiting the growth of or killing a bacterial cell. The present invention provides compositions and methods incorporating and utilizing macolacin antibiotics or derivatives or variants thereof.
C07K 7/60 - Peptides cycliques contenant au moins une liaison peptidique anormale comportant au moins une liaison peptidique anormale dans le cycle cyclisés par le groupe amino-4 de l'acide diamino-2,4 butanoïque
C12P 21/04 - Peptides ou polypeptides cycliques ou pontés, p.ex. bacitracine
80.
COMPOSITIONS AND METHODS TO TREAT METASTATIC GASTROINTESTINAL CANCER
The present invention relates to agents and methods for treating gastrointestinal cancer (e.g., metastatic colorectal cancer) in a subject in need thereof. The method includes suppressing the enzymatic activity of DHODH and/or decreasing the level of creatine via suppression of creatine transporter channel SLC6a8 in the subject. In some embodiments, the suppression step can be carried out by administering to the subject a set of small molecule compounds.
A61K 31/7105 - Acides ribonucléiques naturels, c. à d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
The presently claimed and described technology provides methods of treating adenocarcinoma in a subject by administering a genetically engineered cell expressing a human microbial N-acyl synthase (hm-NAS) gene, an hm-NAS gene, an N-acyl amide, or compositions thereof.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A61K 35/00 - Préparations médicinales contenant des substances ou leurs produits de réaction de constitution non déterminée
A volumetric imaging system implements obtaining raw image data of a sample volume of a sample material, the raw image data comprising light field data of the sample volume acquired using a microlens array disposed in front of a camera; and analyzing the raw image data using an image analysis pipeline configured to localize the objects of interest in the raw image data to obtain classified image data in which the objects of interest have been identified, the image analysis pipeline being configured to process the raw image data to improve signal extraction at depth in the scattering material to maximize localization accuracy.
The invention relates to mutations and alterations in the inflammatory pathway, including IL-18BP and IL-10RB mutations, that are associated with the development of fulminant viral hepatitis following viral infection, such as following hepatitis virus infection. The invention relates to methods for treating or ameliorating viral hepatitis comprising administering IL-18BP, IL-18 antagonist, IFNγ antagonist or inhibitor, and/or IL-10RB or an IL-10 antagonist.
A61K 31/522 - Purines, p.ex. adénine ayant des groupes oxo liés directement à l'hétérocycle, p.ex. hypoxanthine, guanine, acyclovir
A61K 31/675 - Composés du phosphore ayant l'azote comme hétéro-atome d'un cycle, p.ex. phosphate de pyridoxal
A61K 31/513 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime ayant des groupes oxo liés directement à l'hétérocycle, p.ex. cytosine
A61K 31/7072 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p.ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p.ex. cytidine, acide cytidylique ayant deux groupes oxo liés directement au cycle pyrimidine, p.ex. uridine, acide uridylique, thymidine, zidovudine
A61K 31/498 - Pyrazines ou pipérazines condensées en ortho ou en péri avec des systèmes carbocycliques, p.ex. quinoxaline, phénazine
A61K 31/454 - Pipéridines non condensées, p.ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p.ex. pimozide, dompéridone
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p.ex. protecteurs hépatiques, cholagogues, cholélitholytiques
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A61K 38/17 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains
Provided are broadly neutralizing antibodies (bNAbs) and antigen binding fragments thereof that bind with specificity to epitopes expressed by Hepatitis B vims (HBV). The bNAbs target non-overlapping epitopes on the HBV S antigen (HBsAg). Pharmaceutical compositions that contain the bNAbs, or modified bNAbs, are provided. Combinations of the bNAbs are included, and are useful for prophylaxis and therapy of HBV infection, and for inhibiting development of HBV escape mutations in infected individuals. Expression vectors encoding the bNAbs and antigenic fragments of them are included, as are methods of making the bNAbs and antigenic fragments of them. HBV peptides for use as vaccines are provided, and include at least two non-overlapping epitopes from the HBsAg. Diagnostic reagents comprising the bNAbs or antigenic fragments thereof are provided, as are methods of detecting HBV and diagnosing HBV infection.
Antibodies to Zika virus (ZIKV) and dengue 1 virus (DENV1) are provided. The amino acid sequences of the antibodies may be modified. Methods for prophylaxis and/or therapy by administering the antibodies and combinations thereof are provided. Immunological detection methods using the antibodies are provided. Also provided are vaccine compositions which comprise peptides derived from ZIKV and DENV1.
The present disclosure relates to a method of inducing a neuroprotective state comprising administering a Bromodomain and Extra-Terminal motif (BET) inhibitor under conditions effective to induce a neuroprotective state. Also disclosed are methods of preventing and/or treating neurodegenerative disease, methods of reducing microglial inflammation, and methods of restoring microglial homeostasis, where the methods include administering a Bromodomain and Extra-Terminal motif (BET) inhibitor.
A61K 31/5517 - 1,4-Benzodiazépines, p.ex. diazépam condensées avec des cycles à cinq chaînons ayant l'azote comme hétéro-atome d'un cycle, p.ex. imidazobenzodiazépines, triazolam
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61K 31/4709 - Quinoléines non condensées contenant d'autres hétérocycles
A61K 31/551 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p.ex. azélastine, pentylènetétrazole ayant deux atomes d'azote comme hétéro-atomes d'un cycle, p.ex. clozapine, dilazèpe
A61K 31/519 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p.ex. indolizine, bêta-carboline
A61K 31/444 - Pyridines non condensées; Leurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p.ex. amrinone
A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p.ex. azélastine, pentylènetétrazole
A61K 31/472 - Isoquinoléines non condensées, p.ex. papavérine
A61K 31/538 - 1,4-Oxazines, p.ex. morpholine condensées en ortho ou en péri avec des systèmes carbocycliques
87.
ANTIBODIES AND METHODS FOR TREATMENT OF VIRAL INFECTIONS
The present invention provides antibodies that are capable of activating dendritic cell maturation and/or inducing a protective CDS response. The disclosed antibodies can be used to treat or inhibit viral infections, including prophylaxis and treatment of influenza A infection. The invention also provides nucleic acids that encode and immortalized B cells and cultured plasma cells that produce such antibodies.
This disclosure provides novel broadly neutralizing anti-HIV antibodies and antigen-binding fragments thereof. The disclosed anti-HIV antibodies exhibited improved biophysical properties, e.g, reduced polyreactivity, prolonged half-life, while retaining broad and potent neutralization activity. The anti-HIV bNAb variants as disclosed constitute a novel therapeutic strategy for treating and/or preventing HIV infection.
This disclosure is based, at least in part, on an unexpected discovery that the novel nanobodies and variants thereof are able to specifically bind afucosylated or sialylated IgG Fc glycoforms. Glycosylation of the IgG Fc domain is a major determinant of the strength and specificity of antibody effector functions, modulating the binding interactions of the Fc with the diverse family of Fcγ receptors. These Fc glycan modifications, such as removal of the core fucose residue, are newfound clinical markers for predicting severity of diseases, such as diseases caused by dengue virus (DENV) or SARS-CoV-2. However, it remains challenging to accurately distinguish specific IgG glycoforms without costly and time-intensive methods. The novel glycol-specific nanobodies and variants thereof, as disclosed herein, can be used as rapid clinical diagnostics or prognostics to risk stratify patients with viral and inflammatory diseases.
Provided are compositions and methods for producing eukaryotic cells that comprise homozygous modifications. The modifications include homozygous insertions of a modified open reading frame (a “mORF”), and removable surface displayed epitopes that can be used for separating cells that contain the homozygous modifications by Fluorescence-activated cell sorting (FACS). The inserted mORFs are configured so that they are in frame with an endogenous open reading frame and their expression can be controlled by an endogenous promoter. The homozygous insertions are produced using specialized double stranded DNA repair templates and CRISPR-based approaches, which provide for insertion of the homozygous modified ORFs, surface expression of two different epitopes that are separated from the modified ORFs by ribosomal peptide skipping domains, and separation and isolation of cells that contain the homozygous insertions, with concurrent or sequential removal of the epitopes using recombinase-mediated approaches. Cells made using the compositions and methods are also provided.
This disclosure provides novel neutralizing anti-SARS-CoV-2 antibodies or antigen-binding fragments thereof. The disclosed anti-SARS-CoV-2 antibodies constitute a novel therapeutic strategy in protection from SARS-CoV-2 infections.
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur
G01N 33/569 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour micro-organismes, p.ex. protozoaires, bactéries, virus
This disclosure provides novel neutralizing anti-SARS-CoV-2 antibodies or antigen- binding fragments thereof. The disclosed anti-SARS-CoV-2 antibodies constitute a novel therapeutic strategy in protection from SARS-CoV-2 infections.
G01N 33/569 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour micro-organismes, p.ex. protozoaires, bactéries, virus
G01N 33/577 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet faisant intervenir des anticorps monoclonaux
Provided are compositions and methods for selectively reducing the amount of antibiotic resistant and/or virulent bacteria in a mixed bacteria population, or for reducing any other type of unwanted bacteria in a mixed bacteria population. The compositions and methods involve targeting bacteria that are differentiated from other members of the population by at least one unique clustered regularly interspaced short palindromic repeats (CRISPR) targeted DNA sequence. The compositions and methods can be readily adapted to target any bacteria or any bacteria plasmid, or both.
C12N 9/16 - Hydrolases (3.) agissant sur les liaisons esters (3.1)
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur
A61K 31/7105 - Acides ribonucléiques naturels, c. à d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
A01N 63/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des micro-organismes, des virus, des champignons microscopiques, des animaux ou des substances produites par, ou obtenues à partir d
Provided are compositions and methods for selectively reducing the amount of antibiotic resistant and/or virulent bacteria in a mixed bacteria population, or for reducing any other type of unwanted bacteria in a mixed bacteria population. The compositions and methods involve targeting bacteria that are differentiated from other members of the population by at least one unique clustered regularly interspaced short palindromic repeats (CRISPR) targeted DNA sequence. The compositions and methods can be readily adapted to target any bacteria or any bacteria plasmid, or both.
C12N 9/16 - Hydrolases (3.) agissant sur les liaisons esters (3.1)
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur
A61K 31/7105 - Acides ribonucléiques naturels, c. à d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
A01N 63/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des micro-organismes, des virus, des champignons microscopiques, des animaux ou des substances produites par, ou obtenues à partir d
e.g.,e.g., SARS-CoV-2 RNA replicons) that can be trans-packaged for single-cycle delivery into a wide array of cell types and recapitulate all major enzymatic activities of intracellular viral replication. As a low-containment platform, the disclosed RNA replicons are broadly amenable to molecular virology studies and drug development screening efforts.
Provided are compositions and methods for selectively reducing the amount of antibiotic resistant and/or virulent bacteria in a mixed bacteria population, or for reducing any other type of unwanted bacteria in a mixed bacteria population. The compositions and methods involve targeting bacteria that are differentiated from other members of the population by at least one unique clustered regularly interspaced short palindromic repeats (CRISPR) targeted DNA sequence. The compositions and methods can be readily adapted to target any bacteria or any bacteria plasmid, or both.
C12N 9/16 - Hydrolases (3.) agissant sur les liaisons esters (3.1)
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur
A61K 31/7105 - Acides ribonucléiques naturels, c. à d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
A01N 63/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des micro-organismes, des virus, des champignons microscopiques, des animaux ou des substances produites par, ou obtenues à partir d
This disclosure provides novel broadly neutralizing anti-SARS-CoV-2 antibodies or antigen-binding fragments thereof. The disclosed anti-SARS-CoV-2 antibodies constitute a novel therapeutic strategy in protection against SARS-CoV-2 infections.
G01N 33/569 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour micro-organismes, p.ex. protozoaires, bactéries, virus
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
98.
INHIBITORS OF cGAS FOR TREATING AUTOINFLAMMATORY DISEASES AND CANCER METASTASIS
Tri-cyclyl nitrogen-containing heterocyclic compounds
Tri-cyclyl nitrogen-containing heterocyclic compounds
Tri-cyclyl nitrogen-containing heterocyclic compounds
are disclosed. The compounds are inhibitors of human cGAS in interferon-producing cell types. They are thus useful as therapeutic agents for treating cGAS-related autoimmune diseases in humans.
A UV-C decontamination apparatus is used to decontaminate PPEs, such as respiratory masks. The apparatus is formed from a 3D printing process which makes the manufacture and use widespread. The apparatus includes a 3D printed chamber and a lid for enclosing the chamber. At least one UV-C lamp is supported in the chamber. Activation of the lamp is designed to decontaminate the mask supported in the chamber from the lid. An electronic switch assembly permits activation of the lamp only upon locking closure of a lid to the chamber. In a further embodiment, the hook is rotatable on the lid so as to rotate the mask in the chamber upon lamp activation.
A61L 2/10 - Procédés ou appareils de désinfection ou de stérilisation de matériaux ou d'objets autres que les denrées alimentaires ou les lentilles de contact; Accessoires à cet effet utilisant des phénomènes physiques des radiations des ultraviolets
100.
UNRAVELING RECEPTOR-METABOLITE INTERACTIONS IN THE HUMAN MICROBIOME
A61K 31/192 - Acides carboxyliques, p.ex. acide valproïque ayant des groupes aromatiques, p.ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A61K 31/20 - Acides carboxyliques, p.ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p.ex. acides stéarique, palmitique ou arachidique
A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
A61K 35/747 - Lactobacilles, p.ex. L. acidophilus ou L. brevis
